X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SIGA will drive international promotion activities for oral TPOXX, a novel small-molecule drug, approved by the FDA for the treatment of smallpox, while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Meridian Medical Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2024
Details:
TPOXX (tecovirimat), also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
TPOXX is a powerful antiviral drug to vaccinia and allows the safe use of higher doses of vaccinia vectors, there is also the potential it could increase immunotherapeutic outcomes.
Lead Product(s): Vaccinia-based Cancer Therapy,Tecovirimat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: KaliVir Immunotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 15, 2022
Details:
TPOXX (tecovirimat, ST-246®), a novel small-molecule drug, is an orthopoxvirus VP37 envelope wrapping protein inhibits the viral maturation of variola virus and other poxviruses by preventing the formation of a secondary viral envelope.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2022
Details:
TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Patheon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Tecovirimat (TPOXX) was approved by the European Medicines Agency (EMA) in January 2022 with a broader label that covers the treatment of smallpox, monkeypox, cowpox, and complications from vaccination for smallpox.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Funding May 12, 2022
Details:
TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
TPOXX (tecovirimat) receive EMA approval for use in the EU as an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Meridian Medical Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
TPOXX®(Tecovirimat) orally administered IV formulation antiviral drug, is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein indicated for the treatment of human smallpox disease caused by variola virus.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
TPOXX® (tecovirimat) also known as ST-246® is an oral and IV formulation antiviral drug for the treatment of human smallpox disease Under the agreement, Oxford University will sponsor the protocol and study in CAR, and SIGA will provide up to 500 courses of TPOXX at no cost.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Oxford
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
